Skip to main content
Article thumbnail
Location of Repository

Ezetimibe as a potential treatment for non alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?

By Mohamed H. Ahmed and Christopher D. Byrne

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome and is known to be associated with significant insulin resistance and increased risk of cardiovascular disease. .Ezetimibe, an inhibitor of intestinal cholesterol absorption, has been shown to inhibit Niemann-Pick C1-like 1 (NPC1L1) . Interestingly, NPC1L1 is abundantly expressed in human liver as well as in the intestine. Recent reports suggest a potential benefit of ezetimibe in improving hepatic insulin sensitivity and decreasing hepatic inflammation and lipid accumulation. The presence of insulin resistance and excess hepatic fat accumulation are regarded as key factors in the pathogenesis of NAFLD. Therefore, we suggest that urgent studies are needed to assess the potential therapeutic benefit of ezetimibe in treating NAFLD

Topics: RB, RS, RM
Year: 2010
OAI identifier: oai:eprints.soton.ac.uk:158221
Provided by: e-Prints Soton
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://dx.doi.org/10.1016/j.dr... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.